非索普拉赞致复发性肝损伤:非故意再暴露后的再次发作
本文报告一例61岁女性接受非索普拉赞治疗2个月后出现特异质性药物性肝损伤,肝活检示单细胞坏死、界面性肝炎及嗜酸性粒细胞浸润,停药后肝功能恢复。约20个月后非故意再次处方该药,肝损伤复发,生化与组织学特征相似,符合Hy law标准,RUCAM评分由很可能升至极可能。首次发作时药代动力学分析示消除半衰期延长,提示活动性肝损伤期间代谢受损,药物基因组学检测示CYP2C19慢代谢型,但临床相关性有限。
要点
- 非索普拉赞可致特异质性肝损伤,停药后恢复,再次暴露可复发
- 再暴露后符合Hy law标准,RUCAM评分升至极可能
- 详细用药史与上市后监测对识别该不良反应至关重要
核心结论
- 非索普拉赞可导致特异质性药物性肝损伤,且非故意再暴露后可复发,表现为可重复的不良反应。
研究设计与样本
- 个案报告:61岁女性,接受非索普拉赞治疗2个月后出现肝损伤,后非故意再暴露致复发。
主要发现
- 首次发作表现为疲劳和肝酶升高,肝活检示单细胞坏死、界面性肝炎及嗜酸性粒细胞浸润。
- 停药后肝功能恢复正常;约20个月后再暴露后肝损伤复发,生化与组织学特征相似。
- 第二次发作符合Hy law标准,RUCAM评分由很可能升至极可能。
- 首次发作期间药代动力学分析示消除半衰期延长,提示活动性肝损伤期间代谢受损。
- 药物基因组学检测示CYP2C19慢代谢型,但该病例中临床相关性有限。
临床怎么用
- 处方非索普拉赞前应详细询问用药史,警惕肝损伤信号。
- 疑似非索普拉赞肝损伤时应停药并监测肝功能,避免再次暴露。
局限性
- 单个病例报告,因果关系推断受限。
- CYP2C19慢代谢型基因型的临床相关性在本例中有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fexuprazan, a potassium-competitive acid blocker, is increasingly used for the treatment of gastroesophageal reflux disease in South Korea. While generally well tolerated, data regarding its hepatotoxic potential are scarce. We report a case of idiosyncratic drug-induced liver injury in a 61-year-old woman following 2 months of fexuprazan therapy. She presented with fatigue and elevated liver enzymes, and liver biopsy demonstrated single-cell necrosis, interface hepatitis and eosinophilic infiltration-features consistent with drug-induced liver injury. Her liver function normalized after drug discontinuation. However, approximately 20 months later, the patient experienced a recurrence of liver injury after unintentionally being prescribed fexuprazan again. The second episode showed similar biochemical and histological features, fulfilling Hy's law criteria and increasing the RUCAM score from probable to highly probable. Pharmacokinetic analysis during the first episode revealed a prolonged elimination half-life, suggestive of impaired metabolism during active hepatic injury. Pharmacogenetic testing revealed a cytochrome P450 enzyme 2C19 poor metabolizer genotype, although its clinical relevance was limited in this case. This report highlights a rare but reproducible adverse drug reaction to fexuprazan and emphasizes the importance of thorough drug history and postmarketing surveillance. To our knowledge, this is the first report of recurrent fexuprazan-induced liver injury confirmed by unintentional re-exposure.
引用
- Seong SJ, Kweon OS, Yoon YR, et al. Recurrent fexuprazan-induced liver injury following unintentional re-exposure. Br J Clin Pharmacol. 2025. PMID: 40833174. doi:10.1002/bcp.70245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。